Published in J Virol on April 01, 1995
HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med (2012) 2.18
An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc Natl Acad Sci U S A (1997) 1.70
Identification of ligands for RNA targets via structure-based virtual screening: HIV-1 TAR. J Comput Aided Mol Des (2000) 1.02
Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. PLoS Pathog (2011) 0.97
A Tat-induced auto-up-regulatory loop for superactivation of the human immunodeficiency virus type 1 promoter. J Virol (1995) 0.94
Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer. Hum Genet (2014) 0.89
Activation of HIV-1 from latent infection via synergy of RUNX1 inhibitor Ro5-3335 and SAHA. PLoS Pathog (2014) 0.86
Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells. Antimicrob Agents Chemother (1999) 0.79
Inhibition of human immunodeficiency virus type 1 replication in acutely and chronically infected cells by EM2487, a novel substance produced by a Streptomyces species. Antimicrob Agents Chemother (1999) 0.78
HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA. Cell (1986) 12.74
The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell (1986) 10.76
Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism. Cell (1986) 10.71
Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature (1988) 10.15
The trans-activator gene of HTLV-III is essential for virus replication. Nature (1986) 8.65
HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell (1989) 6.11
Post-transcriptional regulation accounts for the trans-activation of the human T-lymphotropic virus type III. Nature (1986) 5.24
The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc Natl Acad Sci U S A (1991) 4.66
HIV-1 Tat protein promotes formation of more-processive elongation complexes. EMBO J (1991) 4.18
HIV-1 Tat protein trans-activates transcription in vitro. Cell (1990) 3.57
Site-directed mutagenesis of two trans-regulatory genes (tat-III,trs) of HIV-1. Science (1988) 3.36
The HIV-1 Tat protein activates transcription from an upstream DNA-binding site: implications for Tat function. Genes Dev (1991) 3.08
Direct interaction of human TFIID with the HIV-1 transactivator tat. Nature (1994) 2.87
HIV-1 Tat acts as a processivity factor in vitro in conjunction with cellular elongation factors. Genes Dev (1992) 2.85
Does HIV-1 Tat induce a change in viral initiation rights? Cell (1993) 2.30
Synergy between HIV-1 Tat and adenovirus E1A is principally due to stabilization of transcriptional elongation. Genes Dev (1990) 2.30
Specific interaction of the human immunodeficiency virus Tat proteins with a cellular protein kinase. Virology (1993) 2.24
Sp1-dependent activation of a synthetic promoter by human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci U S A (1991) 2.17
In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor. J Virol (1993) 2.15
Transcriptional but not translational regulation of HIV-1 by the tat gene product. Nature (1988) 2.15
The HIV-1 long terminal repeat contains an unusual element that induces the synthesis of short RNAs from various mRNA and snRNA promoters. Genes Dev (1990) 2.14
HIV-1 Tat overcomes inefficient transcriptional elongation in vitro. J Mol Biol (1993) 2.12
Activation of human immunodeficiency virus type 1 by DNA damage in human cells. Nature (1988) 1.85
A nuclear translational block imposed by the HIV-1 U3 region is relieved by the Tat-TAR interaction. Cell (1990) 1.73
The human immunodeficiency virus type 1 long terminal repeat specifies two different transcription complexes, only one of which is regulated by Tat. J Virol (1993) 1.67
Characterization of the inducer of short transcripts, a human immunodeficiency virus type 1 transcriptional element that activates the synthesis of short RNAs. Mol Cell Biol (1993) 1.59
Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist. Science (1991) 1.55
Trans-activation of the human immunodeficiency virus long terminal repeat sequences, expressed in an adenovirus vector, by the adenovirus E1A 13S protein. Proc Natl Acad Sci U S A (1988) 1.34
Premature termination and processing of human immunodeficiency virus type 1-promoted transcripts. J Virol (1992) 1.17
Inhibition of type 1 human immunodeficiency virus replication by a tat antagonist to which the virus remains sensitive after prolonged exposure in vitro. Proc Natl Acad Sci U S A (1993) 1.13
Tat transactivation of the human immunodeficiency virus type 1 promoter is influenced by basal promoter activity and the simian virus 40 origin of DNA replication. Proc Natl Acad Sci U S A (1991) 1.04
Cooperative inhibition of NF-kappa B and Tat-induced superactivation of human immunodeficiency virus type 1 long terminal repeat. Proc Natl Acad Sci U S A (1993) 0.98
Restoration of cell surface CD4 expression in human immunodeficiency virus type 1-infected cells by treatment with a Tat antagonist. J Virol (1992) 0.94
Heparin and hormonal regulation of mRNA synthesis and abundance of autocrine growth factors: relevance to clonal growth of tumors. Mol Cell Biol (1991) 0.84
Reconstitution of membranes with individual paramyxovirus glycoproteins and phospholipid in cholate solution. Virology (1979) 2.20
The origin of the heme Cotton effects in myoglobin and hemoglobin. J Am Chem Soc (1971) 1.49
Upregulation of heme oxygenase-1 by Epigallocatechin-3-gallate via the phosphatidylinositol 3-kinase/Akt and ERK pathways. Life Sci (2005) 1.29
Purification and characterization of recombinant Rev protein of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1990) 1.21
Resveratrol suppresses IL-6-induced ICAM-1 gene expression in endothelial cells: effects on the inhibition of STAT3 phosphorylation. Life Sci (2005) 1.15
Fusion of Sendai virus with liposomes: dependence on the viral fusion protein (F) and the lipid composition of liposomes. Virology (1983) 1.14
Enhancement of membrane-fusing activity of sendai virus by exposure of the virus to basic pH is correlated with a conformational change in the fusion protein. Proc Natl Acad Sci U S A (1982) 0.99
Protease activation mutants of Sendai virus: sequence analysis of the mRNA of the fusion protein (F) gene and direct identification of the cleavage-activation site. Virology (1987) 0.98
Restoration of cell surface CD4 expression in human immunodeficiency virus type 1-infected cells by treatment with a Tat antagonist. J Virol (1992) 0.94
Nasal schwannoma: a case report and clinicopathologic analysis. Rhinology (2001) 0.94
Nuclear magnetic resonance studies of the structure of model membrane systems: the effect of surface curvature. Ann N Y Acad Sci (1973) 0.93
Characterization of recombinant HIV-1 Tat and its interaction with TAR RNA. Biochemistry (1992) 0.92
Cytotoxic constituents of Polyalthia longifolia var. pendula. J Nat Prod (2000) 0.90
Regional cerebral blood flow and EEG in patients with epilepsy. Arch Neurol (1978) 0.90
Prevalence and relationship between allergic diseases and infectious diseases. J Microbiol Immunol Infect (2001) 0.88
Assessment of the pathogenetic role of physical exercise in renal stone formation. J Clin Endocrinol Metab (1987) 0.87
Nuclear magnetic resonance studies of the interaction of valinomycin with unsonicated lecithin bilayers. Biochemistry (1973) 0.85
Enhanced calcium bioavailability from a solubilized form of calcium citrate. J Clin Endocrinol Metab (1987) 0.85
Individualization of tobramycin dosage in patients with cystic fibrosis. Pediatr Infect Dis (1985) 0.84
The preservation of urine samples for determination of renal stone risk factors. Lab Med (1987) 0.81
15-Deoxy-Delta(12,14)-prostaglandin J(2) suppresses IL-6-induced STAT3 phosphorylation via electrophilic reactivity in endothelial cells. Life Sci (2006) 0.80
Effect of cAMP elevating agents on carbachol-induced phosphoinositide hydrolysis and calcium mobilization in cultured canine tracheal smooth muscle cells. Cell Calcium (1996) 0.80
Studies on taeniasis in Taiwan. V. Field trial on evaluation of therapeutic efficacy of mebendazole and praziquantel against taeniasis. Southeast Asian J Trop Med Public Health (1986) 0.80
The validity of eye blink rate in Chinese adults for the diagnosis of Parkinson's disease. Clin Neurol Neurosurg (2003) 0.80
Underlying mechanism of regulatory actions of diclofenac, a nonsteroidal anti-inflammatory agent, on neuronal potassium channels and firing: an experimental and theoretical study. J Physiol Pharmacol (2013) 0.78
Variability of tobramycin pharmacokinetics in cystic fibrosis. Pediatr Infect Dis J (1987) 0.78
Attainment of therapeutic fluoride levels in serum without major side effects using a slow-release preparation of sodium fluoride in postmenopausal osteoporosis. J Bone Miner Res (1986) 0.78
Optical activity of dye-apohemoglobin complexes. Biopolymers (1971) 0.77
The fusion-related hydrophobic domain of Sendai F protein can be moved through the cytoplasmic membrane of Escherichia coli. Proc Natl Acad Sci U S A (1986) 0.75
Human antibody and antigen response to IncA antibody of Chlamydia trachomatis. Int J Immunopathol Pharmacol (2007) 0.75
Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor. Antimicrob Agents Chemother (1994) 0.75
Influence of cerebral embolism on brain monoamines. J Neurol Neurosurg Psychiatry (1979) 0.75
Etiological study of 112 patients with primary amenorrhea. Taiwan Yi Xue Hui Za Zhi (1987) 0.75
Sequential use of clomiphene citrate and human menopausal gonadotropin for induction of ovulation. Taiwan Yi Xue Hui Za Zhi (1987) 0.75
Urinary response to oral potassium citrate therapy for urolithiasis in a private practice setting. Clin Ther (1986) 0.75
Photoaffinity labeling of beef liver monoamine oxidase-B by 4-fluoro-3-nitrophenyl azide. Biochem Pharmacol (1987) 0.75
Hypertensive disorders in pregnancy: analysis of 110 cases. Taiwan Yi Xue Hui Za Zhi (1989) 0.75
An ultrastructural assessment of an embolic method of producing cerebral ischemia. Stroke (1977) 0.75
Norplant-2 subdermal contraceptive system: experience in Taiwan. J Formos Med Assoc (1993) 0.75
Testing cerebrovascular functional reserve using 133Xe inhalation measurements of regional cerebral blood flow in health and disease. Acta Neurol Scand Suppl (1977) 0.75
Intrauterine devices Wang S.S Cu 380 as compared to ML Cu 375, Nova T, T Cu 300, 7 Cu 200, Lippes Loop and Ohta Ring: clinical / physiopathological parameters. Adv Contracept Deliv Syst (1992) 0.75
Aplastic anemia and pregnancy. Taiwan Yi Xue Hui Za Zhi (1984) 0.75